Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 8149 results

  1. Technology appraisal committee

    Details, meeting dates and minutes of the independent technology appraisal committees

  2. Public board meetings

    Our board meetings are open to the public. You can download the agenda, papers and minutes for each meeting.

  3. Public board meetings

    Agenda and papers of the NICE public board meeting on 20 March 2024

  4. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTE5)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....

  5. Our projects and partners

    NICE research projects and partners.

  6. Technology appraisal data: appraisal recommendations

    Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  7. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  8. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  9. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.

  10. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

  11. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  12. Guides to developing our guidance

    Resources to help organisations who want to help develop NICE guidance

  13. Register as a stakeholder

    Take part in the production of medical technologies guidance.

  14. Interventional procedures advisory committee

    Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.

  15. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged